After considering the feedback from the second consultation, the evaluation committee has prepared a final evaluation document (FED) on lumasiran for treating primary hyperoxaluria type 1 and submitted it to NICE.
The FED has been sent to consultees for this evaluation who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FED has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FED may be used as the basis for NICE's guidance on the use of the evaluated technology in the NHS in England.
Please note that the appeal period for this evaluation will close at 5pm, Monday 3 April 2023.
This page was last updated: